Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
I'm PortAI, I can summarize articles.
On CNBC's "Mad Money Lightning Round," Jim Cramer advised against buying more AppLovin stock, suggesting to take some profits. Scotiabank raised AppLovin's price target to $575. Cramer labeled 4D Molecular Therapeutics as a "pure spec" and noted its trial enrollment is ahead of schedule. He praised SiTime and D.R. Horton, with analysts raising their price targets. AppLovin shares rose 0.6%, while D.R. Horton gained 0.5%. Ameris Bancorp and 4D Molecular Therapeutics saw slight declines, and SiTime fell 3.7%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments